Aastrom Biosciences to Hold Investor Conference Call

Aastrom Biosciences to Hold Investor Conference Call 


ANN ARBOR, Mich., May 3  /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc.
(NASDAQ:ASTM) announced today that it will host an investor conference call on
Friday, May 6, 2005 at 11:00 a.m. (ET).

Aastrom's call will begin with brief presentations by R. Douglas Armstrong,
Ph.D., Chief Executive Officer and Chairman, and Alan M. Wright, Senior Vice
President Administrative & Financial Operations and Chief Financial Officer. 
The balance of the call will be devoted to questions from registered callers.

Interested parties should call [phone], or toll-free (877) 707- 9628,
fifteen minutes before the start of the call and identify themselves as
registrants of the 'Aastrom Conference Call'.  The call will be simulcast on
the web at http://phx.corporate-ir.net/playerlink.zhtml?c=85924&s=wm&e=1054502,
and archived for 90 days at the same site.

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. (NASDAQ:ASTM) is developing patient-specific products
for the repair or regeneration of human tissues, utilizing the Company's
proprietary adult stem cell technology.  Aastrom's strategic position in the
tissue regeneration sector is enabled by its proprietary Tissue Repair Cells
(TRCs), a mix of bone marrow-derived adult stem and progenitor cells, and the
AastromReplicell(R) System, an industry-unique automated cell production
platform used to produce cells for clinical use. TRCs are the core component of
the products Aastrom is developing for severe bone fractures, ischemic vascular
disease, jaw reconstruction and spine fusion, with Phase I/II level clinical
trials active in the U.S. and EU for some of these indications.

For more information, visit Aastrom's website at http://www.aastrom.com/.

This document contains forward-looking statements, including without
limitation, statements concerning planned clinical trials, product development
objectives, potential product applications, and potential advantages of the
AastromReplicell(R) System, which involve certain risks and uncertainties. The
forward-looking statements are also identified through use of the word "plan,"
and other words of similar meaning.  Actual results may differ significantly
from the expectations contained in the forward-looking statements.  Among the
factors that may result in differences are clinical trial results, potential
product development difficulties, the effects of competitive therapies,
regulatory approval requirements, the availability of financial and other
resources and the allocation of resources among different potential uses. These
and other significant factors are discussed in greater detail in Aastrom's
Annual Report on Form 10-K and other filings with the Securities and Exchange
Commission.

   CONTACTS:
   Kris M. Maly or                         Kevin McGrath
   Becky Anderson                          Cameron Associates
   Investor Relations Department           Phone: [phone]
   Aastrom Biosciences, Inc.
   Phone: [phone]


DATASOURCE: Aastrom Biosciences, Inc.



CONTACT:  Kris M. Maly or Becky Anderson, Investor Relations Department

of Aastrom Biosciences, Inc., [phone]; or Kevin McGrath of Cameron

Associates, [phone]



Web site:  http://www.aastrom.com/

Copyright